Article Information
History
- July 12, 2024.
Article Versions
- Version 1 (February 20, 2024 - 10:36).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- David Stacey, PhD1,2,3,*,
- Liam Gaziano, PhD4,
- Preethi Eldi, PhD2,
- Catherine Toben, PhD5,
- Beben Benyamin, PhD1,3,6,
- S Hong Lee, PhD1,3,6 and
- Elina Hyppönen, PhD1,2,3
- 1Australian Centre for Precision Health, University of South Australia, Adelaide, South Australia, Australia
- 2UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia
- 3South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- 4Harvard Medical School, Boston, Massachusetts, USA
- 5University of Adelaide, Discipline of Psychiatry, Adelaide, South Australia, Australia
- 6UniSA Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- ↵*Corresponding author Dr. David Stacey, Postal address: South Australian Health and Medical Research Institute (SAHMRI), level 8 south, North Terrace, Adelaide, SA 5000, Australia. E-mail: david.stacey{at}unisa.edu.au, Tel: +61 (0)8 8302 8339
Posted July 12, 2024.
A transcriptome-wide Mendelian randomization study in isolated human immune cells highlights risk genes involved in viral infections and potential drug repurposing opportunities for schizophrenia
